Journal of Clinical Epidemiology
Volume 52, Issue 12 , Pages 1197-1200 , December 1999

Lipid-Lowering Medication and Risk of Injury

  • Viktor E. Bovbjerg

      Affiliations

    • Departments of Internal Medicine, Biostatistics, and Health Administration, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA USA
    • Corresponding Author InformationAddress correspondence to: Dr. V. E. Bovbjerg, Health Sciences Center, Box 600, University of Virginia School of Medicine, Charlottesville, VA 22908
    • ,
  • David S. Siscovick

      Affiliations

    • Department of Epidemiology, University of Washington, Seattle, WA USA
    • Department of Medicine, University of Washington, Seattle, WA USA
    • ,
  • Bruce M. Psaty

      Affiliations

    • Department of Epidemiology, University of Washington, Seattle, WA USA
    • Department of Medicine, University of Washington, Seattle, WA USA
    • Department of Health Services, University of Washington, Seattle, WA USA
    • ,
  • Barbara S. McCann

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA USA
    • ,
  • Thomas D. Koepsell

      Affiliations

    • Department of Epidemiology, University of Washington, Seattle, WA USA
    • Department of Medicine, University of Washington, Seattle, WA USA
    • Department of Health Services, University of Washington, Seattle, WA USA
    • ,
  • T.E. Raghunathan

      Affiliations

    • Institute for Social Research, University of Michigan, Ann Arbor, MI USA
    • ,
  • Edward H. Wagner

      Affiliations

    • Department of Health Services, University of Washington, Seattle, WA USA
    • Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, WA USA

,Accepted 1 June 1999.

References 

  1. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality (A quantitative review of primary prevention trials). Br Med J. 1990;301:309–314
  2. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs?. Br Med J. 1992;304:431–434
  3. Engelberg H. Low serum cholesterol and suicide. Lancet. 1992;339:727–729
  4. Katz AM. Cholesterol and violent death. J Mol Cell Cardiol. 1991;23:1343–1344
  5. Cummings P, Psaty BM. The association between cholesterol and death from injury. Ann Intern Med. 1994;120:848–855
  6. Psaty BM, Koepsell TD, Siscovick DS, Wahl P, Logerfo JP, Inui TS. An approach to several problems in using large databases for population-based case-control studies of the therapeutic efficacy and safety of anti-hypertensive medicines. Stat Med. 1991;10:653–662
  7. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit (A new look at old data). Circulation. 1995;91:2274–2282
  8. Scandinavian Simvistatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease (The Scandinavian Simvistatin Survival Study). Lancet. 1994;344:1383–1389
  9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 1995;333:1301–1307
  10. Golomb BA. Cholesterol and violence (Is there a connection?). Ann Intern Med. 1998;128:478–487
  11. The expert panel . Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015–3023

PII: S0895-4356(99)00125-0

Journal of Clinical Epidemiology
Volume 52, Issue 12 , Pages 1197-1200 , December 1999

Article Tools